

Sample Receipt Details:

POD : _____ Temp : _____
 Date & Time : _____ Sample Type : _____
 CS _____ Logistics _____
 Name & Sign: _____ Name & Sign : _____
 Prenatal Sample Yes No **Bill type** MOU Retail Research

TEST REQUISITION FORM

Disease Segment* _____

Each sample must be accompanied by this completed requisition. * Fields are mandatory

Test Details

Comprehensive Tumor Panel (SNVs, InDels, CNVs & Fusions) + TMB + MSI

Test Name: * PD-L1 Dako 22C3 IHC PharmDx **Test Code:** * MGM1785, MGM1789

Sample type:

<input type="checkbox"/> Blood (in EDTA tube)	<input type="checkbox"/> Blood (in streck tube)	<input type="checkbox"/> DNA, Specify Source: _____	<input type="checkbox"/> Buccal swab
<input type="checkbox"/> Amniotic Fluid	<input type="checkbox"/> CVS	<input type="checkbox"/> Cultured CV	<input type="checkbox"/> Cultured amniocytes
<input type="checkbox"/> Fetal Blood (PUBS)	<input type="checkbox"/> Maternal blood for MCC (please send for prenatal studies)	<input type="checkbox"/> Products of Conception (POC), specify tissue: _____	* FFPE tissue Block (Block no.)
<input type="checkbox"/> Fresh Frozen Tissue	<input type="checkbox"/> Saliva	<input type="checkbox"/> Other sample type (specify site) _____	<input type="checkbox"/> DBS/FTA

**PRH4106B
PRH4106B 01/03**

Patient had a blood transfusion Yes No Date of last transfusion ___/___/___ (minimum 3 days of wait time is required for genetic testing)
 Has he/she undergone allogenic bone marrow transplant: Yes No **One wax Block
One Slide**

Patient Details

Name: * Mrs. Champa Egodawatta (In Capital Letters) **D.O.B.** DD MM YY **Age:** * 62Y/F **Gender:** * M / F

Address: _____

Phone: _____ **E-mail I.D:** _____

Clinician Details

Clinician's Name: * Dr. Senaka Kandededara **Hospital Affiliation:** Aegle Omics Pvt Ltd

Address: _____ **Phone :** _____

_____ **Email id :** _____

Date of sample collection * 23/02/2024 YY

I understand that the current analysis is limited to variants which co-relate with disease phenotype/symptoms/terms as mentioned in the clinical details provided by me. Incidental findings which may or may not be actionable are not routinely reported. They can however be provided on request after informed consent from the patient/guardian. As disease phenotype may evolve over time, the appearance of new symptoms/signs may alter test results or their significance: MedGenome laboratories cannot be held responsible for this. A re-analysis or a re-test may be required due to the former; this will be performed (if deemed necessary) at an additional cost. I am authorised to order the above tests as I am the treating physician/consulting physician in this case. I confirm that the patient/guardian (in case of minors) has been provided complete information regarding the test, including its limitations in a language of their understanding.

Dr. MAHESWARA PERERA
MBBS (Cey), MD (Col), Dip RT
Consultant Clinical Oncology
& Radiotherapy

Medical Professional Signature* _____ **Date:** _____ **Place:** _____

Clinical notes/diagnosis: _____

Disease affection status Yes NO **Parental consanguinity present** Yes NO **Age of manifestation:** _____

Affected Siblings Yes NO **Details:** _____

GOVERNING LAW, JURISDICTION AND DISPUTE RESOLUTION

These Terms and Conditions and this Test Requisition Form shall be governed by and construed in accordance with Indian law and the courts in Bangalore shall have exclusive injunctive jurisdiction. In the event of any dispute, controversy or claim whatsoever arising from these Terms and Conditions and/or this Test Requisition Form, the parties shall undertake to make every effort to reach an amicable settlement within fifteen (15) days upon reference of the dispute by any party through discussions among the concerned representatives of parties, failing which the dispute, controversy or claim shall be settled by Arbitration by a Sole Arbitrator appointed by the 'President-Arbitration Centre-Karnataka', Bangalore as per Indian Arbitration and Conciliation Act, 1996 as amended from time to time. The venue of arbitration shall be Bangalore and it shall be conducted in English language. The award passed by the Sole Arbitrator shall be final and binding upon the parties.

NOTICE

All notices, statements or other communication required or permitted to be given or made shall be in writing and in English language. Such notices will deliver by hand or sent by prepaid post with recorded delivery, or facsimile transmission addressed to the intended recipient at the address mentioned in this Test Requisition Form.

INDEPENDENT PARTIES

All parties effected hereunder are independent entities and neither of the parties are an agent, employee or joint venture of the other and they shall not represent themselves as such to any third parties.

REFUND

Refund of fees for any reason has to be claimed by the Patient or the guardians of the Patients within 90 days from the date of delivery of report.

Patient/Guardian Authorization

By my signature below I attest to the following:

I have read and I understand the information provided on this form.

Patient Consent (sign here or on the consent document)

I have read the Informed Consent document and I give permission to MedGenome to perform genetic testing as described. I also give permission for my specimen / genetic data to be used in (de-identified) studies at MedGenome to improve genetic testing for other patients.

By agreeing to this informed consent below, I am confirming that I understand the benefits, risks and limitations associated with genetic testing. Furthermore, I am affirming that I recognize the seriousness of conditions for which {I am/my child} being tested, and that disease descriptions, prognoses, and treatment options have been made available to me by {my/my child's} health care provider. Finally, if I have the legal authorization to provide this informed consent on behalf of another person, I am attesting that the sample provided belongs to that person.

 Patient/Guardian Name Mrs. Champa Egodawatta

First Name

Middle Name

Last Name

Date of Birth: mm/dd/yyyy

Patient/Guardian Signature*

Date:

Place:

Father Name

Mother Name

Signature*

Date and time

Signature*

Date and time

Relationship with the proband


Note :

Signature of both parents is requested for prenatal testing.

For trio testing, each parent should provide separate informed consent for the sequencing of his or her sample.

16 DEC 2024

Handwritten signature




See CA

2018 - 2021 - 2024

3rd Lpt Patient

See panel Analysis



Dr. MAHENDRA PERERA
MBS (Gen), MR (Gen), Dip RT
Consultant in Clinical Oncology
& Radiotherapy
Principal Investigator - Clinical Trials

CONFIDENTIAL LABORATORY REPORT

Member of Clinical and Laboratory Standards Institute, U.S.A.

ASIRI
LABORATORIES**ASIRI**
LABORATORIES
LIVE MORE
A Softlogic Group CompanyAsiri Laboratories Kandy, 907, Peradeniya Road, Kandy
T. + 94 81 785 0404-5 prlab@asiri.lk**HISTOPATHOLOGY**Block and sides of this specimen/s
will be retained ONLY for six months
after the date of this report. Specimen
will be kept for one week.

** IP/AKH/AKH **

Page 1 of 2

UHID : 150174524
 REFERENCE No. : 05 4069 23/02/24 IP No. : AKH0050635
 SAMPLE DATE & TIME : 23/02/2024 19:20 AGE : 61 Y/F
 REPORT DATE & TIME : 03/03/2024 13:54 AHK2500180 / AKH2430454
 PATIENT : MRS. CHAMPA EGODAWATTA [ROOM NO.ICUB]
 REFERRED BY : DR H.H. MANJULA KUMARA HERATH

TEST : HISTOPATHOLOGY REPORT..

Specimen : Right partial nephrectomy - renal tumor

Macroscopy : The partial nephrectomy specimen measuring 60x30x20 mm.
 Outer surface is partly covered with peri nephric fat.
 The renal capsule stretched but intact.

The cut surface reveals a well demarcated haemorrhagic
 tumour measuring 12x9x8 mm.

The lesion is located 3 mm away from the deep resection
 margin macroscopically.

Microscopy : The right renal tumour shows the appearances of a clear
 cell renal cell carcinoma which is comprised of numerous
 tubular structures of varying sizes, formed by large cells
 with clear cytoplasm and small pyknotic nuclei (ISUP Grade
 1). The tumour is well demarcated by a relatively thick
 capsule.
 Areas of necrosis are not seen.
 Foamy cells or calcifications are not identified.
 No sarcomatous areas are seen.
 The renal capsule, or perinephric fat are free of tumour
 invasion.
 However few tumour nodules separate from main mass are
 noted within the perinephric adipose tissue.
 The rest of the kidney shows focal chronic tubulo
 interstitial nephritis.
 All the margins are well away from the tumour.
 The closest resection margin is 3 mm from the tumour.
 The perinephric fat margin is within 2 mm from the tumour
 nodules present within the perinephric fat.

CTD next page



CONFIDENTIAL LABORATORY REPORT

Member of Clinical and Laboratory Standards Institute, U.S.A.



Member of



Member ID # 383029



Member Number: 4790



35+ Years of Excellence

ASIRI LABORATORIES



ASIRI LABORATORIES

LIVE MORE
A Softlogic Group Company

Asiri Laboratories Kandy, 907, Peradeniya Road, Kandy
T. + 94 81 785 0404 - 5 prlab@asiri.lk

HISTOPATHOLOGY

Block and sides of this specimen/s will be retained ONLY for six months after the date of this report. Specimen will be kept for one week.

** IP/AKH/AKH **

Page 2 of 2

UHID : 150174524
 REFERENCE No. : 05 4069 23/02/24
 SAMPLE DATE & TIME : 23/02/2024 19:20
 REPORT DATE & TIME : 03/03/2024 13:54 AHK2500180 / AKH2430454
 PATIENT : MRS. CHAMPA EGODAWATTA [ROOM NO.ICUB]
 REFERRED BY : DR H.H. MANJULA KUMARA HERATH
 IP No. : AKH0050635
 AGE : 61 Y/F

Diagnosis :

Right partial nephrectomy : Clear cell renal cell carcinoma.
 Fuhrman/ISUP Nuclear grade 1
 pT3aNxMx

SYNOPTIC REPORTING :

Partial nephrectomy

Specimen Laterality: Right
 Tumor Focality: Unifocal
 Tumor Size: Greatest dimension 1.2cm
 Histologic Type: Clear cell renal cell carcinoma
 Histologic Grade (WHO / ISUP): G1
 Tumor Extent: Separate tumour nodules in the perinephric fat
 Sarcomatoid Features: Not identified.
 Rhabdoid Features: Not identified.
 Tumor Necrosis: Not identified.
 Lymphovascular Invasion: Not identified.
 Margin Status: All margins negative for invasive carcinoma.
 Regional Lymph Node Status: No regional lymph nodes submitted.
 pT3aNxMx- AJCC 8th Edition (Invasion of perinephric fat)

PRH4106

Dr. Palitha Ratnayake
 MBBS, D.path, MD (PATHOLOGY)
 Consultant Pathologist

NATIONAL HOSPITAL
KANDY

IMMUNOHISTOCHEMISTRY REPORT

Name: C Egodawatta

Age: 56Y

Sex: Female

Ward/ Clinic: 47

BHT/ Clinic Number: 23993

Histology Reference number: KN 1265/21

IHC Number: 295/21

Specimen/ Site: Right partial nephrectomy specimen


IMMUNOHISTOCHEMICAL ASSESSMENT:

SMA and desmin highlighted attenuated smooth muscle fibers confirming that the excision represent RCC embolus within perihilar vessel.

03/03/2021



Dr. Palitha Ratnayake
Cons. Pathologist


Cons. Pathologist
MBBS D. Path MD (Pathology)

NATIONAL HOSPITAL
KANDY
HISTOLOGY REPORT

FOR HOSPITAL
ATTENTION

JHC - 295

Name: C Egodawatta

Age: 56Y

Sex: Female

Ward/ Clinic: 47

BHT/ Clinic Number: 23993

Histology Reference number: KN 1265/21

Specimen/ Site: Right partial nephrectomy specimen

Macroscopy:

- a. Right partial nephrectomy specimen measuring 25x20x20 mm which is partly covered with perinephric fat.
The cut surface reveals a well circumscribed nodule measuring 18x12x13mm
The lesion is within 1mm from the resection margin which contains normal renal tissue macroscopically.
The cut surface of the tumour shows haemorrhagic areas.
- b. Chest wall nodule: A soft tissue mass measuring 35x15x10 mm

Microscopy:

The sections through the renal nodule reveal a large nodule of clear cell renal cell carcinoma with areas of haemorrhages.

The tumour nodule is present in the hilar fibro connective and adipose tissue, possibly with in a dilated large blood vessel. Bundles of smooth muscle are present in the periphery of the tumour nodule, suggesting the vascular nature.

The lesion is completely excised with clear margins.

The adjacent ureter or kidney tissue present are free of tumour invasion.

Diagnosis:

Deposit of clear cell renal cell carcinoma at the hilum/ possibly within a blood vessel

01/03/2021


Dr. Palitha Ratnayake
Cons. Pathologist

Dr. Palitha Ratnayake
Cons. Pathologist
MBChB, Path MD (Pathology)



Name of patient : Mrs.Champa Egodawatta Age : 61 Yr Sex : F
Scan Region : Post contrast CT chest, abdomen and pelvis
Requested by : Dr.Manjula Herath. MBBS, MD. Date : 30/01/2024
Consultant Genito Urinary Surgeon.
Radiologist : Dr (Mrs) Samantha Perera. MBBS,DCH, MD (RAD) CT No : 559866

CT SCAN REPORT

CT CHEST ABDOMEN AND PELVIS :

HISTORY: Known single kidney. Recurrent RCC, Partial nephrectomy done twice, MRI – local recurrence.

TECHNIQUE: Pre and post oral , rectal and IV contrast axial scans of abdomen and pelvis with coronal & sagittal reformats.

REPORT:

Left Kidney is absent.

Rt Kidney : 11.4x 6 cm

There is a 2x2x2.1cm heterogeneously enhancing lesion seen in the inferior region of the left kidney. It has reduced contrast enhancement the adjacent renal cortex. No calcifications seen within it. The lesion extend into the renal sinus fat with compression of the inferior calyx without infiltrating into it. Renal pelvis is normal.

No hydronephrosis or hydroureter in the left side.

No renal vein or IVC thrombi.

No para aortic lymph adenopathy.

Single renal artery is demonstrated.

Urinary bladder is smoothly distended.

No free fluid in the abdomen and pelvis.

No evidence of bone metastasis

Liver is normal in size and show normal density.

There is solitary 2x2cm lesion in segment VI of the liver. It is hypodense in non-contrast study and shows Peripheral nodular contrast enhancement in the arterial and venous phases with centripetal contrast filling

In the delayed phase.

No intrahepatic or CBD duct dilatation.

GB, spleen and adrenal glands are unremarkable.

Stomach and bowel loops are normal.

Trachea and main bronchi are normal.

Both lungs are clear.

No focal lung nodules.

No mediastinal or hilar lymph adenopathy.

No pleural or pericardial effusions.

No rib erosions or other bony abnormalities.

PTO

COMMENT:

**Recurrent renal cell CA in the inferior pole of single right kidney.
No liver, lung or bone metastasis.
Known haemangioma in the segment VI of the liver.**



**Dr. (Mrs) Samantha Perera. MBBS,DCH, MD(Radiology)
Consultant Radiologist,
National Hospital, Kandy**

Thank you very much for referring this patient

**Dr. (Mrs) Samantha Perera,
MBBS, DCH, MD (Radiology)
Consultant Radiologist
National Hospital - Kandy**



Name:	Mrs.Champa Egodawatta	Age	61 Yrs	Sex:	Female
Requested by:	Dr. S.L.Kandegedara. MBBS,MD				
Indication:	L/Renal cell CA, USS – Mass in the lower pole of right kidney.				
MRI Scan	MRI abdomen and Pelvis and MRCP	No.	00557209		

Daté- 23.01.2024

Report

Left kidney is absent.
No masses in the left renal bed.

Right Kidney BPL – 11.4cm

There is a well defined 2.3x2x2cm (APxTransxCC) lesion in the inferior pole of the right kidney anteriorly.

It is heterogeneous in intensity in T1W, slightly hyper intense in T2W and shows contrast enhancement

which is less than the normal renal cortical enhancement.

Lesion is causing fluid restriction.

Mild sub serosal fat infiltration is seen. Gerota's fascia is not infiltrated.

The lesion is in close contact with the inferior calyx.

Single right renal artery is noted.

No renal vein or IVC thrombosis.

No para aortic lymphadenopathy.

Liver is normal in size and show normal intensity.

There is a single well defined 2x2x1.8 cm lesion in segment VI sub capsularly.

It is low in signal intensity in T1, high in T2 and show centripetal enhancement in contrast study.

Largest lesion is 12x15mm in segment VI.

No intra hepatic bile ducts or CBD dilatation.

Portal vein is normal in size.

Normal flow void is seen in the portal vein.

Spleen is normal in size and show normal contrast enhancement.

Adrenal glands are normal..

Pancreas is normal in size and show normal intensity in T1W and T2W images.

No focal lesions.

No pancreatic duct dilatation.

No peri pancreatic fluid collections.

PTO

Comment:

- MRI appearance are in keeping with local recurrence of RCC in the lower pole of solitary right kidney.
- Known liver haemangioma.
- No para aortic LN or liver metastasis



Dr.(Mrs) Samantha Perera
Consultant Radiologist,
National Hospital, Kandy.

Department of Nuclear Medicine

Whole body PET-CT Report

Name : Mrs.Champa Egodawatta

Age/Sex :60Y/F

Ref. No : RC00009023

Referred By: Dr.S.L.Kandegedara

PET CT No:936/22

Date:12.11.2022

Clinical Details :

- Diagnosed renal cell CA in solitary right kidney in November 2018.
- Partial nephrectomy done in November 2018 and histology confirmed clear cell renal CA.
- Tumor recurrence of right kidney lower pole in February 2021.
- Exicion of tumor recurrence done.
- Follow up with interferon upto September 2022.

Indication : PET CT for further evaluation

Technique : Patient's serum glucose level was 110mg/dl at the time of the study. Patient was injected with 6.21mCi of F-18 FDG in right anticubital Fosse.

PET CT scan was performed from vertex to mid thigh after resting for 60minutes.

Corresponding low dose contrast enhanced spiral CT of the body was acquired. PET CT and Fused PET CT were reviewed at the work station.

REPORT

Head & Neck

- Right lobe of thyroid gland has a FDG avid nodule in lower pole 1.4cm x 1.0cm and SUV max 11.0.
- There are no abnormal attenuating or enhancing foci in the cerebral hemispheres, cerebellum or in the brain stem.
- No FDG avid foci in the skull vault or base of the skull.
- Normal physiological distribution of FDG uptake and is noted in brain parenchyma
- Soft tissues of the neck shows normal FDG activity.
- No FDG avid foci in the neck.
- No significant cervical lymphadenopathy on CECT.
- Bilateral orbits, pharynx, para pharyngeal soft tissues and soft tissues of the neck are normal.

Chest

- There are no focal parenchymal nodules or air space opacifications in the lung.
- No FDG avid foci in the lung fields.
- The chest wall, soft tissues of the chest and mediastinum appear normal.
- No prominent or enlarged FDG avid lymphnode in the axillae, mediastinum or hilar.
- No pleural or peri cardiac effusions.

Abdomen & Pelvis

- Enlarged liver with fatty infiltration.
- Solitary right kidney has normal parenchymal activity. High FDG avidity in renal pelvicalyceal system is due to excreted urine.
- No FDG avid lesions in the liver, spleen, pancreas, kidneys or adrenal glands.
- They show normal parenchymal attenuation in CT.
- Abdominal wall, peritoneum and retroperitoneum appear normal with no FDG avid foci.
- No abnormal mass lesions or fluid collections in the abdomen or pelvis.
- No prominent or enlarged or FDG avid lymphnodes in the abdomen or pelvis.

Muscular skeletal and miscellaneous

- No FDG avid foci in the visualized bones from skull base to the pelvis and upper thigh.

IMPRESSION :

1. **No FDG avid tumor recurrence in right kidney or the para renal space.**

Mild dilatation of renal pelvicalyceal system.

2. **No metabolically active metastasis in to liver, lung or the bones and no FDG avid lymph nodes.**
3. **Hypermetabolic solitary nodule in right lobe of thyroid gland.**


Dr. (Mrs.) Eranga Perera
M.B.B.S. MD (Radiology)
Consultant Radiologist